Samuel Goldberg

Researcher in Psychedelic Science

Data updated

Papers

11 publications

Trials

0 clinical trials

Research Footprint

Samuel Goldberg appears in 11 tracked papers (2020–2025), most studied alongside Psilocybin, DMT and MDMA, across Depressive Disorders, Anxiety Disorders and Safety & Risk Management.

Most-cited paper: The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis (230 citations).

Frequent co-authors: Otto Simonsson, Peter Hendricks and Wojciech Osika.

Background & Research

Samuel B. Goldberg is a researcher working at the intersection of psychedelic science, contemplative practice, and population health. His work focuses on large‑scale and longitudinal analyses that probe how lifetime and recent use of classic psychedelics relate to engagement with meditation practices, health behaviours, and markers of physical and mental well‑being. Goldberg frequently applies epidemiological methods to survey datasets from the United States and the United Kingdom to identify associations and temporal patterns rather than conducting interventional trials.

Goldberg's contributions emphasise nuanced, data‑driven characterisations of who uses psychedelics and how such use correlates with subsequent or concurrent meditation practice and lifestyle factors. Key outputs include cross‑sectional and longitudinal studies on classic psychedelic use and current meditation practice, investigations of whether psychedelic experiences may benefit meditation, and analyses linking psychedelic exposure to health behaviour and physical health outcomes in population samples. His research supports a more integrative understanding of psychedelics within broader behavioural and mental‑health contexts and highlights directions for hypothesis generation and future experimental work.